Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Selective sustainable hydrodeoxygenation of bioaromatics (Selective HDO)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: Belgium
Call: MSCA Postdoctoral Fellowships 2021 (HORIZON-MSCA-2021-PF-01, 2021)
Start date: 2022-05-01
End date: 2024-04-30
Duration (months): 24.0
Total project cost (EUR): 186304.0
EU funding (EUR): 186304.0
Participants: 1
Project status: CLOSED

The depletion of fossil resources and the requirement to significantly reduce our CO2 footprint made the production of chemicals from non-edible biorenewable feedstocks an intensive contemporary research field. Remarkably, amongst the bioderived chemicals available, bioaromatics are still scarce. A typical feature of biobased platform molecules is their high oxygen content, which is in sharp contrast with current base chemicals obtained via a classical petrochemical approach. While petrochemical industry requires efficient and selective oxidation protocols, biorenewables on the other hand require the reverse, i.e. efficient and selective reduction reactions, necessitating new reaction development. Chemical and (bio)catalytic processes on biorenewable resources (e.g. wood, cloves, gallnuts) deliver a variety of oxygenated arenes (guaiacols, syringols, catechols, pyrogallols). Hydrodeoxygenation (HDO) reactions on these biobased arene building blocks can give access to functional chemicals suitable for the chemical industry. Though extensively researched, selective HDO on these oxygenated arenes is still poorly developed. Therefore, the main objective of this proposal is to develop selective HDO in catechols, guaiacols, pyrogallols, and syringols. Our approach involves sustainable activation of Ar-OH and Ar- (OH)2 with a renewable and cheap reactant, and subsequent reduction with a renewable reductant. As catalysts readily available and cheap base metals will be explored rather than scarce and expensive precious transition metals. Both homogeneous and heterogeneous catalysis will be evaluated.

Keywords: biorenewable chemicals,sustainable chemistry,bioaromatics,reduction,phenols,anisoles,carbonate
Reversing vaccine hypo-responsiveness (REVERSE)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Prevention,  Diagnosis and T reatment of Human Diseases
Panel description: Medical technologies  and tools for prevention, diagnosis and treatment of human diseases, therapeutic approaches and interventions , pharmacology, preventative  medicine, epidemiology and public health , digital medicine
Countries involved: Netherlands
Call: ERC ADVANCED GRANTS (ERC-2021-ADG, 2021)
Start date: 2022-10-01
End date: 2027-09-30
Duration (months): 60.0
Total project cost (EUR): 2372681.0
EU funding (EUR): 2372681.0
Participants: 1
Project status: SIGNED

Prevention of infectious diseases through vaccination is one of the greatest achievements of medicine, yet there is growing realisation that vaccine immunogenicity and efficacy varies greatly across populations in high- versus low/middle- income countries (LMIC) and in urban- versus rural areas within one country. For example, whereas vaccination of volunteers in Europe with attenuated malaria vaccine can result in 100% protection, the efficacy drops to only 29% when tested in Africa, where it is needed most. Other vaccines, such as rotavirus, BCG, yellow fever and Ebola show similar trends in either immunogenicity or efficacy. It is my ambition to take on the challenge of understanding the mechanisms underlying vaccine hypo-responsiveness across populations and find ways to REVERSE it. I hypothesize that the variation in the immunological network, shaped by exposure to microorganisms and parasites, as well as by cellular metabolic state of populations residing in distinct environmental conditions, underlies vaccine hypo-responsiveness and can be REVERSEd by immunological and metabolic interventions. To address this, I will compare unique cohorts from LMIC and Europe, using single cell technologies to understand the immunological and metabolic networks that govern innate and adaptive immune responses. Not only blood but also secondary lymphoid organs will be studied to gain critical information on key cell-cell interactions within germinal centers, and how they are influenced by cells beyond B and T cells, discovering key pathways underlying hypo-responsiveness. I will take advantage of increasing availability of clinically approved modulatory compounds to target these pathways to improve vaccine responses in our in vitro models. I will also perform a proof of concept clinical trial to establish a pipeline for translating the fundamental insights gained, to human testing, and pave the way to new horizons for vaccines to show their full potential worldwide.

Keywords: vaccine,hypo responsiveness,immunology,immunometabolism,single cell technology,low middle income country,geographical variation
Revolutionary therapeutic treatment for stopping progression of Parkinson's disease (ReTreatPD)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: Finland
Call: EIC Accelerator Open (HORIZON-EIC-2022-ACCELERATOR-01, 2022)
Start date: 2023-05-01
End date: 2025-04-30
Duration (months): 24.0
Total project cost (EUR): 4083500.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: CLOSED

Parkinson's disease (PD) is a common neurodegenerative disorder, affecting over 10 million people worldwide, whereof 1.2 million in the EU. This chronic disabling disease affects the central nervous system, causing severe motor and non-motor symptoms. The high disease burden for patients and their family also comes with a big price tag for society, which is expected to increase dramatically with an ageing population. In EU the annual cost is 14 B€ currently. The causes of PD are unknown and there is a broad spectrum of pathologies that ultimately lead to the loss of dopamine producing neurons in the brain. The current dopamine substitution treatments alleviate some of the symptoms, however, there is no cure for PD nor any disease-modifying therapies. Herantis has developed a new pharmaceutical HER-096 with the ability to affect PD pathology and potential to revolutionise the treatment of PD, thus alleviating the huge burden it now causes patients and healthcare.

Keywords: blood brain barrier penetrating,disease modifying pd therapy,parkinson s disease,cerebral dopamine neurotrophic factor,proteostasis,a synuclein,cdnf
Space Architecture design and prototyping in planetary analogue environments (ArchiSpace)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Staff Exchanges
Action type: Marie Skłodowska-Curie actions
Panel: Environment and Geosciences
Countries involved: Italy,Netherlands,Portugal,France,Hungary,Morocco
Call: MSCA Staff Exchanges 2023 (HORIZON-MSCA-2023-SE-01, 2023)
Start date: 2024-11-01
End date: 2028-10-31
Duration (months): 48.0
Total project cost (EUR): 1744057.14
EU funding (EUR): 1485800.0
Participants: 8
Project status: SIGNED

In this decade we aim to come back to the Moon to stay. It is therefore crucial to develop reliable and safe settlements that adequately protect astronauts physical and mental well-being from all possible threats that the hostile environment of extraterrestrial space presents. ArchiSpace aims to design and build sub-systems prototypes (e.g., walls, roofs, living spaces, etc.) of human infrastructures to be built on planetary surfaces, which will be tested in planetary analogue environments. This project represents the first effort, to the best of our knowledge, to use environmental and geological setting analogues as a base to define architectural constraints, sketch design and prototypes to be used in future space human settlements. Archispace is pioneering a new fields of interdisciplinary and intersectoral research in Europe by bridging geology/space sciences and architecture/space architecture. Geology/space science is crucial because the subsurface plays a fundamental role in the selection of the landing sites and the location of 'human-focused' habitats. Architecture/space architecture has a key role in designing comfortable, safe and functional habitats. Our complementary partners are leaders in their respective sectors and hold the necessary know-how and/or technology level to achieve the Archispace objectives. In addition, the human settlements to be developed will involve (new) low impact, low-cost and light operations and ISRU materials. This planetary “green” approach could also be applied on Earth. The project will create, through the planned secondments, common standards, methods and prototypes for the development of space bases on Moon and Mars in the future; which will be tested in three joint field activities (e.g., in Morocco analogues sites). Thus, Archispace promotes an innovative international, inter-sectoral and interdisciplinary research and innovation collaboration that can contribute to Europe's competitiveness and growth.

Keywords: space architecture,planetary analogues,mars and moon space habitats,3d printing,space settlements for astronauts
B Cell Engineering and Tertiary Lymphoid Structure Induction via Biomaterials for Cancer Immunotherapy (BeaT-IT)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Prevention,  Diagnosis and T reatment of Human Diseases
Panel description: Medical technologies  and tools for prevention, diagnosis and treatment of human diseases, therapeutic approaches and interventions , pharmacology, preventative  medicine, epidemiology and public health , digital medicine
Countries involved: Germany
Call: ERC STARTING GRANTS (ERC-2021-STG, 2021)
Start date: 2022-07-01
End date: 2027-06-30
Duration (months): 60.0
Total project cost (EUR): 1488762.5
EU funding (EUR): 1488762.5
Participants: 1
Project status: SIGNED

Recent clinical evidence points to a potential new direction in immuno-oncology: utilizing B cells and B cell-associated tertiary lymphoid structures (TLS). B cells display diverse immunological actions, including antibody production, antigen presentation, cytokine secretion and TLS induction. They have a dual role: they can initiate and reinforce anti-cancer immunity but B cells can also acquire regulatory phenotypes. To open up a new immunotherapeutic paradigm, I aim to understand how to optimally activate B cells, using nano-/biomaterials which load and precisely release a variety of agents to stimulate B cells and to suppress B cell regulatory phenotypes. Furthermore, I will manufacture porous scaffolds based on injectable microgels or via 3D printing with microgel fibers to induce TLS formation. The scaffolds with tunable porosity will allow B cells and other immune/stromal cells to infiltrate, arrange and expand, and soluble factors to diffuse. Moreover, the scaffolds can be easily functionalized with different chemical cues to stimulate B cells for TLS formation, such as CXC-chemokine ligand 13 and interleukin-7. This will help us understand TLS induction. Importantly, I will use ex vivo engineered TLS to study what microenvironmental factors influence their functionality. Subsequently, in vivo formation of B cell-associated TLS will be induced by the scaffolds. B cell activation and TLS induction will be combined for tumor therapy, and potential abscopal effect of the treatment to address metastases will be studied. The materials will be further combined with checkpoint inhibitors and chemotherapy to reach synergism. In addition, the new therapeutic strategies will be tested in patient-derived tumors established in humanized mice. BeaT-IT aims to understand optimal B cell activation and TLS formation with nano-/biomaterials to establish a new direction in immuno-oncology, which is anticipated to realize an upcoming breakthrough in cancer immunotherapy.

Keywords: immunomodulatory nano biomaterials,cancer nanomedicine,tertiary lymphoid structures,drug delivery,tumor targeting,combination cancer therapy
Central roles of mycobacterial type VII secretion systems in intra- and inter-kingdom warfare (CombaT7)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Synergy grants
Action type: ERC actions
Countries involved: Netherlands,Germany,United Kingdom,Switzerland
Call: ERC SYNERGY GRANTS (ERC-2024-SyG, 2024)
Start date: 2025-04-01
End date: 2031-03-31
Duration (months): 72.0
Total project cost (EUR): 10837150.0
EU funding (EUR): 10837150.0
Participants: 4
Project status: SIGNED

Bacteria interact with their environment via specialised secretion systems that deliver proteins outside of the cell. Due to a bias in research efforts, for many years such systems were assumed to be unique to Gram-negative bacteria. A major exception is the type VII secretion system (T7SS), which is widespread in Gram-positive bacteria and actinobacteria, including the important human pathogen Mycobacterium tuberculosis. The T7SS is a complex secretion apparatus that exports folded proteins and even protein complexes. While secreted substrates are well-known for being crucial players in host-pathogen interactions, our recent data indicate that specific substrates of the relevant opportunistic pathogen Mycobacterium abscessus and the fish pathogen Mycobacterium marinum are also involved in interbacterial antagonism. This makes T7SSs important factors to understand microbial interactions, also for the understudied part of the microbial world. While the mechanism of secretion via T7SSs remains little understood, our preliminary data show that not only their roles but also their substrates are more diverse than thus far thought. Here, we unite leading experts in microbiology, structural biology, cell biology, and biophysics to spearhead research on mycobacterial T7SSs and their roles in both interbacterial and host-pathogen interactions. In this unique consortium, we will (i) define the full trans-envelope T7SS by atomic force microscopy and cryo-electron microscopy, (ii) study the mechanism of transport by creating translocation intermediates, (iii) expand the set of T7SS substrates by extensive proteomics and bioinformatics analysis, and (iv) visualise the role of T7SS in bacterial warfare and host-pathogen interactions using microfluidics, innovative lung-on-a-chip infection models and time-lapse microscopy. This will deliver a deep mechanistic understanding of the diverse roles of mycobacterial T7SSs and provide clues to exploit these systems to combat infections.

Keywords: type vii secretion tuberculosis mycobacterium membrane complex toxin host pathogen interactions cryo electron tomography single particle analysis atomic force microscopy microfluidics time lapse microscopy
To a Fair, Inclusive, Circular and Healthy cities: Valorisation of phosphogypsum wastes into commercial products through sustainable and circular processes (FIC-FIGHTERS)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Food, Bioeconomy Natural Resources, Agriculture and Environment
Theme: Bio-Environment
Destination: Other Bio-environnement destinations
Action type: Innovation actions
Countries involved: Spain,Finland,North Macedonia,Serbia,Italy,Belgium,Croatia,France,Germany,Portugal,Romania
Call: Circular Cities and Regions Initiative (CCRI)’s circular systemic solutions (HORIZON-CL6-2023-CIRCBIO-02, 2023)
Start date: 2024-06-01
End date: 2028-05-31
Duration (months): 48.0
Total project cost (EUR): 11813624.5
EU funding (EUR): 9991736.73
Participants: 29
Project status: SIGNED

FIC-FIGHTERS is a local democracy project. It is the search for new economic models deliberately agreed to manage of waste that harms the natural and cultural heritage. It is a space for discussion on the adoption of alternatives for wastes that has been accumulating near our cities for decades. The project will involve different local actors, industries, authorities, SMEs, RTD centers, and universities to inclusively scale up to TRL6-7 waste recovery processes under the premises of the circular economy, focusing on the valorization of phosphogypsum waste (PG) to generate sustainable raw materials for use in the paper, cement, batteries, fertilizers and detergents industries. For 48 months, the different actors, in cooperation with the CCRI, will be involved in making the new circular business models a reality. The project will: 1) Build a mobile pilot plant (TRL7) based on optimised results and digital twin of the processes to demonstrate the sustainable production of raw materials (sodium sulfate, REE and P, aluminum hydroxide, ammonium sulfate and precipitated calcium carbonate) for different industries, starting from phosphogypsum and other wastes. 2) Create a PG forum for local discussions and develop local workshops in each of the 6 case studies, including citizen participation, addressing socio-economic, environmental and regulation aspects of the new circular business models developed to become a reality and reaching trust and acceptance. 3) Address the flexibility and replicability of the valorization processes by involving 7 case studies and create the first known PG Exploitation Portal aiming to identify, characterise, and reach all European cities with same problematic. 4) Contribute to knowledge exchange in clustering and CCRI events; creating a Community of Practice and making the results of the project publicly available and exploitable, addressing IP protection. 5) Provide guidelines to reach circularity based on LCA, LCC, social and H&S studies.

Keywords: environment,sustainability,resources,democracy,new business models,local participation
Illiberal Peacebuilding and Authoritarian Regime Survival: Evidence from Postwar Syria (ILIBRLSYRIA)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Social Sciences and Humanities
Countries involved: Austria
Call: MSCA Postdoctoral Fellowships 2024 (HORIZON-MSCA-2024-PF-01, 2024)
Start date: 2026-04-01
End date: 2028-03-31
Duration (months): 24.0
Total project cost (EUR): 230184.72
EU funding (EUR): 230184.72
Participants: 1
Project status: SIGNED

The past two decades have seen a decline in the liberal world order; states increasingly move away from peaceful negotiation, justice, and human rights. Instead, they rely on an emerging model of authoritarian conflict management, which depends on excessive violence, coercive negotiations, and hierarchical structures of power to suppress internal conflicts. However, recognising that state coercion is crucial, yet not sufficient, to construct and sustain a long-term order, scholars have recently begun to examine the illiberal peacebuilding practices employed by authoritarian regimes to construct and consolidate postwar order. This is an emerging area of inquiry in which many authoritarian practices and their impacts on local communities remain understudied in the academic literature. Focusing on Syria, ILIBRLSYRIA combines cutting-edge empirical strategy with interdisciplinary approaches to investigate the processes and impacts of novel illiberal peacebuilding practices deployed by the regime to control space and society in areas recaptured from defeated rebel forces. ILIBRLSYRIA is structured around three in-depth and interrelated studies, each focusing on one illiberal practice identified through extensive field observation. These include the remobilisation of former rebels, the diversion of international aid, and the stimulation of refugee migration. The theoretical and empirical findings will provide original insights into the realities and complexities of authoritarian postwar governance in contexts often viewed through the simplistic lens of military victory by incumbent regimes. ILIBRLSYRIA is highly relevant for policy circles. It will offer evidence-based knowledge and contribute to ongoing debates focused on developing strategies to counteract and mitigate the impacts of illiberal peacebuilding, particularly at a time when such practices are on the rise worldwide.

Keywords: illiberal peace building,authoritarian conflict management,authoritarianism,middle east politics,state building,syria
Translational Research and Innovation in Ophthalmology Vision - Centre of Excellence (TRIO-VI CoE)

Framework: Horizon Europe — Widening Participation and Strengthening the European Research Area
Programme: Widening participation and spreading excellence
Theme: Improved access to Excellence
Destination: Improved access to Excellence
Action type: Coordination and support actions
Panel: Information Science and Engineering
Countries involved: Poland,United Kingdom,France
Call: Teaming for Excellence (HORIZON-WIDERA-2023-ACCESS-01, 2023)
Start date: 2025-01-01
End date: 2030-12-31
Duration (months): 72.0
Total project cost (EUR): 15000000.0
EU funding (EUR): 15000000.0
Participants: 6
Project status: SIGNED

Eye diseases affect the daily lives of 2.2 billion people globally and have a significant socio-economic impact. However, recent advances have rapidly progressed our understanding of the mechanisms of ophthalmic diseases, opening unprecedented opportunities in the field of eye therapeutics. The development of new technologies (robotics, AI) and health services (virtual clinics) offers new solutions to improve the quality of life of ophthalmology patients and to reduce the costs and burdens for national healthcare systems. In the TRIO-VI project we address these challenges, focusing on translating the latest advances in science and technical research into practice in vision care. Together with strategic partners from UCL and Sorbonne, we create a centre of excellence – the International Center for Eye Research (ICTER CoE) in Warsaw, a sub-unit of the Institute of Physical Chemistry of the Polish Academy of Sciences. Unlocking scientific and translational potential of ICTER CoE guarantees tremendous impact on society, science, education and health by accelerating introduction of therapies and new solutions in vision care. It will boost the rapidly growing biophotonics and biomedical engineering industry in Poland by introducing new devices in ophthalmology. As a result of TRIO-VI, we anticipate a considerable improvement in R&D&I capabilities in ICHF and ICTER, through enhanced education, training, and integrated skill development for all employee groups, with a focus on excellence, gender equality, and multidisciplinary collaboration. Thus, we aim to strengthen the R&I system in Poland, attract EU funding, increase visibility of Polish R&D institutions in EU and beyond, and substantially become a gamechanger for paradigm of ophthalmology in Central Europe. By boosting the changes ICTER CoE will become a lighthouse for the Polish Academy of Sciences, the largest research institute network in the country, and the scientific landscape in Poland and in the region.

Keywords: ophthalmology,vision impairment,safe vision,eye disease therapy,biochemistry physics of vision,optical imaging,ophthalmic surgery